Literature DB >> 16443203

Effect of allopurinol on brain adenosine levels during hypoxia in newborn piglets.

Peter J Marro1, Om P Mishra, Maria Delivoria-Papadopoulos.   

Abstract

Adenosine, a purine nucleoside, is a potent inhibitory neuromodulator in the brain which may provide an important endogenous neuroprotective role during hypoxia-ischemia. Allopurinol, a xanthine oxidase inhibitor, blocks purine degradation and may result in the accumulation of purine metabolites, including adenosine, during hypoxia. The present study determines the effect of allopurinol administration prior to hypoxia on brain levels of adenosine and purine metabolites in the newborn piglet. Twenty-two newborn piglets (age 3-7 days) were studied: 5 untreated normoxic and 6 allopurinol-treated normoxic controls were compared to 5 untreated hypoxic and 6 allopurinol-treated hypoxic animals. Brain tissue energy metabolism was continuously monitored during hypoxia by (31)P NMR spectroscopy. Brain tissue levels of purines increased in both hypoxic groups during hypoxia, however, there were significantly higher increases in brain tissue levels of adenosine (66.5 +/- 30.5 vs. 19.4 +/- 10.7 nmol/gm), P < 0.01 and inosine (265 +/- 97.6 vs. 162.8 +/- 38.3 nmol/gm), P = 0.05 in the allopurinol-treated hypoxic group. Allopurinol inhibits purine degradation under severe hypoxic conditions and results in a significant increase in brain tissue levels of adenosine and inosine. The increased accumulation of CNS adenosine during hypoxia which is seen in the allopurinol-treated animals may potentiate adenosine's intrinsic neuroprotective mechanisms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16443203     DOI: 10.1016/j.brainres.2005.11.061

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  12 in total

Review 1.  Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal.

Authors:  Tuhina Neogi; Jacob George; Sushma Rekhraj; Allan D Struthers; Hyon Choi; Robert A Terkeltaub
Journal:  Arthritis Rheum       Date:  2012-02

Review 2.  Intracellular Signaling Cascades in Bipolar Disorder.

Authors:  Gregory H Jones; Carola Rong; Aisha S Shariq; Abhinav Mishra; Rodrigo Machado-Vieira
Journal:  Curr Top Behav Neurosci       Date:  2021

3.  Anti-nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of A1 adenosine receptors.

Authors:  A P Schmidt; A E Böhmer; C Antunes; C Schallenberger; L O Porciúncula; E Elisabetsky; D R Lara; D O Souza
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

Review 4.  New antioxidant drugs for neonatal brain injury.

Authors:  Maria Luisa Tataranno; Serafina Perrone; Mariangela Longini; Giuseppe Buonocore
Journal:  Oxid Med Cell Longev       Date:  2015-01-05       Impact factor: 6.543

Review 5.  Role of Antioxidants in Neonatal Hypoxic-Ischemic Brain Injury: New Therapeutic Approaches.

Authors:  Olatz Arteaga; Antonia Álvarez; Miren Revuelta; Francisco Santaolalla; Andoni Urtasun; Enrique Hilario
Journal:  Int J Mol Sci       Date:  2017-01-28       Impact factor: 5.923

6.  Neuroprotection with hypothermia and allopurinol in an animal model of hypoxic-ischemic injury: Is it a gender question?

Authors:  Javier Rodríguez-Fanjul; Cristina Durán Fernández-Feijóo; Míriam Lopez-Abad; Maria Goretti Lopez Ramos; Rafael Balada Caballé; Soledad Alcántara-Horillo; Marta Camprubí Camprubí
Journal:  PLoS One       Date:  2017-09-20       Impact factor: 3.240

Review 7.  Current and Emerging Therapies in the Management of Hypoxic Ischemic Encephalopathy in Neonates.

Authors:  Jayasree Nair; Vasantha H S Kumar
Journal:  Children (Basel)       Date:  2018-07-19

8.  Effect of allopurinol in addition to hypothermia treatment in neonates for hypoxic-ischemic brain injury on neurocognitive outcome (ALBINO): study protocol of a blinded randomized placebo-controlled parallel group multicenter trial for superiority (phase III).

Authors:  Christian A Maiwald; Kim V Annink; Mario Rüdiger; Manon J N L Benders; Frank van Bel; Karel Allegaert; Gunnar Naulaers; Dirk Bassler; Katrin Klebermaß-Schrehof; Maximo Vento; Hercilia Guimarães; Tom Stiris; Luigi Cattarossi; Marjo Metsäranta; Sampsa Vanhatalo; Jan Mazela; Tuuli Metsvaht; Yannique Jacobs; Axel R Franz
Journal:  BMC Pediatr       Date:  2019-06-27       Impact factor: 2.125

9.  CeRebrUm and CardIac Protection with ALlopurinol in Neonates with Critical Congenital Heart Disease Requiring Cardiac Surgery with Cardiopulmonary Bypass (CRUCIAL): study protocol of a phase III, randomized, quadruple-blinded, placebo-controlled, Dutch multicenter trial.

Authors:  Raymond Stegeman; Maaike Nijman; Nicolaas J G Jansen; Manon J N L Benders; Johannes M P J Breur; Floris Groenendaal; Felix Haas; Jan B Derks; Joppe Nijman; Ingrid M van Beynum; Yannick J H J Taverne; Ad J J C Bogers; Willem A Helbing; Willem P de Boode; Arend F Bos; Rolf M F Berger; Ryan E Accord; Kit C B Roes; G Ardine de Wit
Journal:  Trials       Date:  2022-02-23       Impact factor: 2.279

10.  Neuroprotective therapies after perinatal hypoxic-ischemic brain injury.

Authors:  Felipe Goñi de Cerio; Idoia Lara-Celador; Antonia Alvarez; Enrique Hilario
Journal:  Brain Sci       Date:  2013-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.